Samuel Kintz Biography and Net Worth

Co-founder, Chief Executive Officer, and Member of the Board of Directors of Enliven Therapeutics

Sam is a co-founder of Enliven Therapeutics and serves as the Chief Executive Officer and a member of the Board of Directors. Prior to co-founding Enliven, Sam was an Executive Director of Research at AbbVie and the Head of Research at AbbVie Stemcentrx. Sam started at Stemcentrx as Senior Director, Strategy and Business Development.

Sam has also served as Vice President, Business Development and Applications, at Biodesy, a South San Francisco-based biotech startup developing and commercializing novel protein conformation technology for small-molecule drug discovery.

Additionally, Sam has worked at Roche Venture Fund, where he triaged and sourced investment opportunities in the life sciences industry. He has also worked as a medicinal chemist at Genentech, where he designed and synthesized small-molecule drugs for the treatment of cancer and neurodegenerative diseases.

Sam earned both an M.B.A. and a B.S. in Chemistry, with Honors, from Stanford University.

What is Samuel Kintz's net worth?: The estimated net worth of Samuel Kintz is at least $18.03 million as of April 17th, 2025. Mr. Kintz owns 985,392 shares of Enliven Therapeutics stock worth more than $18,032,674 as of April 24th. This net worth evaluation does not reflect any other investments that Mr. Kintz may own. Additionally, Mr. Kintz receives a salary of $866,410.00 as Co-founder, Chief Executive Officer, and Member of the Board of Directors at Enliven Therapeutics. Learn More about Samuel Kintz's net worth.
How old is Samuel Kintz?: Mr. Kintz is currently 38 years old. There are 5 older executives and no younger executives at Enliven Therapeutics. Learn More on Samuel Kintz's age.
What is Samuel Kintz's salary?: As the Co-founder, Chief Executive Officer, and Member of the Board of Directors of Enliven Therapeutics, Inc., Mr. Kintz earns $866,410.00 per year. Learn More on Samuel Kintz's salary.
How do I contact Samuel Kintz?: The corporate mailing address for Mr. Kintz and other Enliven Therapeutics executives is 309 Beacon Street Suite 300 Office 341, Brookline MA, 02446. Enliven Therapeutics can also be reached via phone at 617-927-9989 and via email at ir@imaratx.com. Learn More on Samuel Kintz's contact information.
Has Samuel Kintz been buying or selling shares of Enliven Therapeutics?: Within the last three months, Samuel Kintz has sold $82,100.00 in shares of Enliven Therapeutics stock. Most recently, Samuel Kintz sold 5,000 shares of the business's stock in a transaction on Thursday, April 17th. The shares were sold at an average price of $16.42, for a transaction totalling $82,100.00. Following the completion of the sale, the chief executive officer now directly owns 985,392 shares of the company's stock, valued at $16,180,136.64. Learn More on Samuel Kintz's trading history.
Who are Enliven Therapeutics' active insiders?: Enliven Therapeutics' insider roster includes Rahul Ballal (Director), Rishi Gupta (Director), Richard Heyman (Chairman of the Board of Directors), Benjamin Hohl (Chief Financial Officer and Head of Corporate Development), Samuel Kintz (Co-founder, Chief Executive Officer, and Member of the Board of Directors), Joseph Lyssikatos (Co-founder, Chief Scientific Officer), and Anish Patel (Co-founder and Chief Operating Officer). Learn More on Enliven Therapeutics' active insiders.
Are insiders buying or selling shares of Enliven Therapeutics?: In the last twelve months, insiders at the sold shares 67 times. They sold a total of 1,443,876 shares worth more than $32,811,792.39. The most recent insider tranaction occured on April, 21st when insider Joseph P Lyssikatos sold 5,000 shares worth more than $80,350.00. Insiders at Enliven Therapeutics own 29.2% of the company. Learn More about insider trades at Enliven Therapeutics.
Information on this page was last updated on 4/21/2025.

Samuel Kintz Insider Trading History at Enliven Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
4/17/2025	Sell	5,000	$16.42	$82,100.00	985,392
3/17/2025	Sell	12,500	$20.83	$260,375.00	990,392
10/18/2024	Sell	924	$30.00	$27,720.00	1,002,892
10/9/2024	Sell	16,710	$28.15	$470,386.50	1,003,816
10/7/2024	Sell	2,730	$27.50	$75,075.00	1,033,793
10/4/2024	Sell	12,206	$27.51	$335,787.06	1,036,523
10/1/2024	Sell	526	$27.54	$14,486.04	1,048,729
8/26/2024	Sell	12,000	$22.89	$274,680.00	1,049,255
7/31/2024	Sell	2,270	$27.56	$62,561.20	1,061,255
7/25/2024	Sell	12,000	$24.92	$299,040.00	1,063,525
6/25/2024	Sell	12,000	$21.66	$259,920.00	1,075,525
5/28/2024	Sell	12,000	$23.18	$278,160.00
4/25/2024	Sell	12,000	$16.89	$202,680.00
4/11/2024	Sell	47,709	$25.04	$1,194,633.36
3/25/2024	Sell	12,000	$17.56	$210,720.00
1/25/2024	Sell	12,000	$15.69	$188,280.00
12/26/2023	Sell	12,000	$14.64	$175,680.00
12/22/2023	Sell	8,175	$13.05	$106,683.75
12/20/2023	Sell	7,779	$13.01	$101,204.79
11/3/2023	Sell	8,026	$13.08	$104,980.08
9/25/2023	Sell	12,000	$13.81	$165,720.00

See Full Table

Samuel Kintz Buying and Selling Activity at Enliven Therapeutics

Enliven Therapeutics Company Overview

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. The company is headquartered in Boulder, Colorado.

Today's Range

Now: $18.30

$17.36

$18.57

50 Day Range

MA: $19.44

$14.91

$22.46

2 Week Range

Now: $18.30

$13.30

$30.03

Volume

249,987 shs

Average Volume

264,770 shs

Market Capitalization

$896.77 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.03

Samuel Kintz Biography and Net Worth

What is Samuel Kintz's net worth?

How old is Samuel Kintz?

What is Samuel Kintz's salary?

How do I contact Samuel Kintz?

Has Samuel Kintz been buying or selling shares of Enliven Therapeutics?

Who are Enliven Therapeutics' active insiders?

Are insiders buying or selling shares of Enliven Therapeutics?